|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1800 CONCORD PIKE, P.O. BOX 15437 |
Address2 |
|
| City | WILMINGTON |
State | DE |
Zip Code | 19850-5437 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 54073-12
|
||||||||
|
6. House ID# 349750000
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Sarah Arbes |
Date | 4/21/2025 3:00:06 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R.946 - Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act
HR 1262/ S 932, Give Kids A Chance Act
Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language)
Issues related to Inflation Reduction Act (IRA) consideration of small molecule drugs, biologics, and genetically targeted technologies
Issues related to expanding/amending the orphan drug exclusion in IRA
Issues related to pharmacy benefit manager (PBM) reform
Issues related to e-labeling
Issues related to the price and manufacture of inhaled medicines
Issues related to the IRAs drug price negotiation program
Issues related to drug pricing
Issues related to the US manufacturing of pharmaceuticals
Issues related to importation of drugs
Issues related to FDA Orange Book patent listings
Issues related to environmental sustainability
Issues related to FDA modernization
Policies related to international reference pricing for pharmaceuticals
Policies related to 340B rebate model for IRA compliance
Policies related to the definition of a qualifying single source drug under the IRA
Pediatric rare disease priority review voucher
Reauthorization of the pediatric priority review voucher program
Company sustainability policy issues
General issues related to health equity in rare disease and clinical trials
General issues related to vaccine safety, efficacy, and access
General issues related to rare disease and orphan drugs
General issues related to ACIP recommendations
Education to Hill staff on next generation propellant and PFAS
FDA modernization policy issues
Tariffs/trade policies related to tariffs on pharmaceuticals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), White House Office, Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katie |
Jones |
|
|
|
Sarah |
Arbes |
|
|
|
Caroline |
Quat |
|
|
|
Art |
Motta |
|
|
|
Lisa |
Langenderfer |
|
|
|
Emily |
Mace |
|
Intern, Rep. Bruce Westerman (AR-4); Legislative Assistant & Counsel, Rep. Bruce Westerman (AR-4); Senior Policy Advisor & Counsel, Rep. H. Morgan Griffith (VA-9); Deputy Chief of Staff & Counsel, Rep. Larry Bucshon (IN-8) |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Definition of Qualified Single Source Drug (QSSD) for purposes of Medicare drug price negotiation
E-labeling - allowing FDA to finalize a rule to allow digital versions of prescriptions
Medicare patient access to rare disease therapies
Centers for Medicare and Medicaid Innovation (CMMI) policy issues
Value-based payment arrangements
Efforts to improve coding, coverage, and access for rare disease therapies
Medicare drug price negotiation
Part B and Part D drugs
Medicare Part D reform and inflation penalties
Medicaid Drug Rebate Program proposed rule
Issues related to the digital communication of prescribing information for drugs
General issues related to diagnostic reimbursement
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katie |
Jones |
|
|
|
Caroline |
Quat |
|
|
|
Art |
Motta |
|
|
|
Lisa |
Langenderfer |
|
|
|
Emily |
Mace |
|
Intern, Rep. Bruce Westerman (AR-4); Legislative Assistant & Counsel, Rep. Bruce Westerman (AR-4); Senior Policy Advisor & Counsel, Rep. H. Morgan Griffith (VA-9); Deputy Chief of Staff & Counsel, Rep. Larry Bucshon (IN-8) |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
e-labeling- allowing health care providers to receive prescribing information for drugs electronically rather than in paper form from manufacturers
Issues related to PBM reform
US manufacturing of pharmaceuticals
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katie |
Jones |
|
|
|
Caroline |
Quat |
|
|
|
Art |
Motta |
|
|
|
Lisa |
Langenderfer |
|
|
|
Emily |
Mace |
|
Intern, Rep. Bruce Westerman (AR-4); Legislative Assistant & Counsel, Rep. Bruce Westerman (AR-4); Senior Policy Advisor & Counsel, Rep. H. Morgan Griffith (VA-9); Deputy Chief of Staff & Counsel, Rep. Larry Bucshon (IN-8) |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R.591 - Defending American Jobs and Investment Act
HR 1414 - Cameron's Law, to restore orphan drug research tax credit
H.R.1990 - American Innovation and R&D Competitiveness Act of 2025
H.R.4695 - Unfair Tax Prevention Act
Expiring provisions of the Tax Cut and Jobs Act law
Tax reform in budget reconciliation
Trade and tariffs (general education, country-specific tariffs, sector-specific tariffs)
pharmaceutical manufacturing (general education)
Issues related to tariffs
Issues related to the deduction of research and development expenditures
Education on tax in preparation for 2025 tax legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katie |
Jones |
|
|
|
Caroline |
Quat |
|
|
|
Art |
Motta |
|
|
|
Lisa |
Langenderfer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Issues related to IP and patents
Issues related to FDA Orange Book patent listings
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Quat |
|
|
|
Art |
Motta |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
INS |
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |